Details of the Drug Pharmacogenomic Perturbation Atlas

Piperazine Drug Info

Anthalazine; Antiren; Diethylenediamine; Diethyleneimine; Dispermine; Eraverm; Hexahydropyrazine; Lumbrical; PZE; Piperazidine; Piperazin; Pipersol; Upixon; Uvilon; Vermex; Vermizine; Wurmirazin; Piperazin [German]; Piperazin [Germany]; Piperazine Dihydrochloride Dihydrochloride Hydrate; Piperazine [USAN]; Piperazine anhydrous; Piperazinium oleate; Pyrazine hexahydride; LTBB000432; Piperazine [UN2579] [Corrosive]; Eraverm (VAN); PIPERAZINE (HEXAHYDRATE); Piperazine (USP); Piperazine Hexa-Hydrate; Piperazine, anhydrous; Pyrazine, hexahy; Vermizine (TN); Worm-away; Asca-Trol No. 3; Worm-A-Ton; Hexahydro-1,4-diazine; 1,4-Diazacyclohexane; 1,4-Diethylenediamine; 1,4-Piperazine

Therapeutic Class

Antinematodal Agents

Cross-matching ID

PubChem CID

4837

ChEBI ID

CHEMBL28568

CAS Number

CAS 110-85-0

TTD Drug ID

D01XLM

INTEDE Drug ID

DR1297

ACDINA Drug ID

D00535

General Information of Drug (ID: DMTY9LU)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Spliceosome	1.52	5.33e-1	101/150 (67.33%)	HNRNPA3;PRPF19;PUF60;...
Tight junction	1.47	6.17e-1	130/169 (76.92%)	CDC42;CLDN8;ERBB2;...
Porphyrin and chlorophyll metabolism	1.46	5.09e-1	23/43 (53.49%)	PPOX;UGT2B28;HMOX2;...
Proximal tubule bicarbonate reclamation	1.46	4.49e-1	21/23 (91.3%)	AQP1;GLS;SLC4A4;...
D-Glutamine and D-glutamate metabolism	1.44	4.44e-1	5/5 (100%)	GLS;GLS2;GLUD1
Ribosome biogenesis in eukaryotes	1.43	4.29e-1	52/108 (48.15%)	RPP38;GTPBP4;NHP2;...
ECM-receptor interaction	1.40	4.76e-1	80/88 (90.91%)	THBS1;LAMC1;COL9A2;...
One carbon pool by folate	1.36	5.56e-1	15/20 (75%)	TYMS;DHFR;AMT
Epstein-Barr virus infection	1.36	5.27e-1	189/202 (93.56%)	CCND2;PDIA3;CCNA1;...
AGE-RAGE signaling pathway in diabetic complications	1.31	6.23e-1	97/100 (97%)	CDC42;F3;AGT;...
Staphylococcus aureus infection	1.17	6.30e-1	72/95 (75.79%)	DEFB1;C5AR1;KRT23;...
ABC transporters	1.16	6.12e-1	37/45 (82.22%)	DEFB1;TAP2;ABCC10;...
Small cell lung cancer	1.16	6.00e-1	90/92 (97.83%)	LAMC1;LAMA4;DDB2;...
Human papillomavirus infection	1.16	5.87e-1	284/331 (85.8%)	CDC42;THBS1;CCND2;...
mRNA surveillance pathway	1.16	5.73e-1	71/98 (72.45%)	TARDBP;CASC3;PNN;...
Amyotrophic lateral sclerosis	1.16	5.59e-1	267/364 (73.35%)	GRIA2;ERBB4;HSPA5;...
Endocrine and other factor-regulated calcium reabsorpti...	1.15	5.60e-1	49/53 (92.45%)	CLTB;CALB1;VDR;...
Salmonella infection	1.15	5.58e-1	198/249 (79.52%)	CDC42;CTNNB1;AHNAK;...
Phagosome	1.14	5.67e-1	118/152 (77.63%)	MPO;THBS1;CYBB;...
Histidine metabolism	1.14	5.73e-1	16/22 (72.73%)	AOC1;HAL;MAOB
Protein processing in endoplasmic reticulum	1.13	5.77e-1	127/171 (74.27%)	RAD23B;PDIA3;STT3A;...
Arginine biosynthesis	1.13	5.64e-1	17/22 (77.27%)	ARG1;GLS;GLS2;...
Colorectal cancer	1.13	5.51e-1	84/86 (97.67%)	EREG;AREG;CTNNB1;...
Basal cell carcinoma	1.12	5.69e-1	41/63 (65.08%)	BMP4;CTNNB1;DDB2;...
Pancreatic cancer	1.12	5.61e-1	75/76 (98.68%)	CDC42;DDB2;AKT3;...
Pathogenic Escherichia coli infection	1.12	5.52e-1	152/197 (77.16%)	CDC42;CLDN8;MYO5A;...
Gastric cancer	1.11	5.76e-1	122/149 (81.88%)	CTNNB1;DDB2;JUP;...
Kaposi sarcoma-associated herpesvirus infection	1.09	6.02e-1	172/193 (89.12%)	CTNNB1;AKT3;STAT1;...
Hepatitis B	1.09	6.03e-1	151/162 (93.21%)	CCNA1;DDB2;AKT3;...
PI3K-Akt signaling pathway	1.08	6.33e-1	317/354 (89.55%)	EREG;AREG;THBS1;...
FoxO signaling pathway	-1.40	2.05e-1	118/131 (90.08%)	GADD45G;BCL6;PIK3R2;...
Insulin resistance	-1.41	2.07e-1	96/108 (88.89%)	CPT1A;OGT;PRKCD;...
Vibrio cholerae infection	-1.41	1.99e-1	44/50 (88%)	ATP6V0D1;ATP6V1H;ATP6V1G1;...
Malaria	-1.42	1.97e-1	44/50 (88%)	TLR2;SDC2;TGFB1;...
Starch and sucrose metabolism	-1.42	2.02e-1	25/36 (69.44%)	UGP2;PYGM;GYS1;...
Pyruvate metabolism	-1.43	2.03e-1	41/47 (87.23%)	PDHB;LDHA;ACACB;...
Selenocompound metabolism	-1.43	2.06e-1	11/17 (64.71%)	SEPHS1;TXNRD1;PAPSS2;...
mTOR signaling pathway	-1.51	1.59e-1	114/154 (74.03%)	CAB39L;DDIT4;RRAGC;...
Sphingolipid metabolism	-1.52	1.47e-1	32/49 (65.31%)	ASAH1;SPTLC1;SMPD1;...
Oxidative phosphorylation	-1.53	1.47e-1	93/133 (69.92%)	NDUFS4;NDUFA5;NDUFB2;...
Fructose and mannose metabolism	-1.55	1.35e-1	30/33 (90.91%)	PFKFB4;PFKL;MPI;...
Gastric acid secretion	-1.58	1.06e-1	63/76 (82.89%)	ATP4A;KCNJ15;ATP1B1;...
Estrogen signaling pathway	-1.59	9.98e-2	119/137 (86.86%)	KRT33A;FKBP4;CALML3;...
Salivary secretion	-1.59	1.04e-1	76/93 (81.72%)	ATP1B1;CALML3;CST3;...
Pancreatic secretion	-1.59	1.08e-1	87/102 (85.29%)	SCT;CTRB2;SCTR;...
Sulfur metabolism	-1.59	1.15e-1	9/10 (90%)	PAPSS2;TST;PAPSS1;...
Folate biosynthesis	-1.60	1.21e-1	23/26 (88.46%)	FPGS;TH;TPH1;...
Longevity regulating pathway	-1.60	1.21e-1	90/151 (59.6%)	PIK3R2;SOD1;HDAC1;...
Insulin signaling pathway	-1.61	1.29e-1	121/137 (88.32%)	PKLR;PIK3R2;CRK;...
Nitrogen metabolism	-1.61	1.35e-1	16/17 (94.12%)	CA5A;CA14;CPS1;...
Allograft rejection	-1.63	1.28e-1	32/38 (84.21%)	HLA-G;HLA-DRA;HLA-E;...
Fat digestion and absorption	-1.64	1.36e-1	35/43 (81.4%)	GOT2;SCARB1;PLA2G2D;...
Collecting duct acid secretion	-1.65	1.37e-1	22/27 (81.48%)	ATP6V0D1;ATP6V1G1;ATP6V1C1;...
Pantothenate and CoA biosynthesis	-1.67	1.30e-1	14/21 (66.67%)	ALDH1B1;BCAT2;AASDHPPT;...
Autoimmune thyroid disease	-1.67	1.43e-1	46/53 (86.79%)	TSHR;TPO;HLA-G;...
Rheumatoid arthritis	-1.68	1.62e-1	78/93 (83.87%)	ATP6V1H;ATP6V1G1;TLR2;...
Graft-versus-host disease	-1.68	2.00e-1	32/42 (76.19%)	HLA-G;HLA-DRA;HLA-E;...
Hematopoietic cell lineage	-1.70	2.04e-1	90/99 (90.91%)	CD7;IL3RA;HLA-DRA;...
Glycerolipid metabolism	-1.74	1.62e-1	44/61 (72.13%)	ALDH9A1;AGK;PNLIPRP2;...
Viral myocarditis	-1.84	1.12e-1	53/60 (88.33%)	HLA-DRA;HLA-E;HLA-DQB1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Ewing sarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
SK-ES-1	CVCL_0627	Homo sapiens	1.11uM - 10uM	24H

Brain

Glioma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
GI-1	CVCL_1230	Homo sapiens	1.11uM - 10uM	24H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MDA-MB-468	CVCL_0419	Homo sapiens	1.11uM - 10uM	24H

Breast ductal carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
T-47D	CVCL_0553	Homo sapiens	1.11uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
SNU-407	CVCL_5004	Homo sapiens	1.11uM - 10uM	24H

Endometrium

Endometrial adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
HEC-108	CVCL_2926	Homo sapiens	1.11uM - 10uM	24H

HEC-1-A	CVCL_0293	Homo sapiens	1.11uM - 10uM	24H

HEC-251	CVCL_2928	Homo sapiens	1.11uM - 10uM	24H

HEC-265	CVCL_2929	Homo sapiens	1.11uM - 10uM	24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
CJM	CVCL_U797	Homo sapiens	3.33uM - 10uM	24H

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
JHH-5	CVCL_1320	Homo sapiens	1.11uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
NCI-H1573	CVCL_1483	Homo sapiens	1.11uM - 10uM	24H

NCI-H838	CVCL_1594	Homo sapiens	1.11uM - 10uM	24H

Lung squamous cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
BEN	CVCL_1081	Homo sapiens	1.11uM - 10uM	24H

HCC95	CVCL_1276	Homo sapiens	1.11uM - 10uM	24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
NCI-H2110	CVCL_1529	Homo sapiens	1.11uM - 10uM	24H

Muscle

Rhabdomyosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-204	CVCL_0134	Homo sapiens	3.33uM	24H

Ovary

Ovarian clear cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
OVTOKO	CVCL_3114	Homo sapiens	1.11uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
22Rv1	CVCL_1045	Homo sapiens	1.11uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
IGR-37	CVCL_1303	Homo sapiens	1.11uM - 10uM	24H

Mel-HO	CVCL_1402	Homo sapiens	1.11uM - 10uM	24H

SH-4	CVCL_1692	Homo sapiens	1.11uM - 10uM	24H

Urinary bladder

Bladder transitional cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
CAL-29	CVCL_1109	Homo sapiens	1.11uM - 10uM	24H